Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.
Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
“Precision medicine” is a term we have heard a lot over the last two decades, promising to improve health outcomes by pairing the patient with the right treatment. In cancer, we do this primarily with biomarkers. Our understanding of biomarkers – signatures of key features of a tumor – and their role in disease has […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Season 2 of our MedCity Pivot Podcast launches today with a conversation about how AI can be leveraged to transform precision medicine.
Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center.
GE Healthcare is preparing for its spinoff from GE, which is planned for the first week of January. The company’s split will allow it to operate under a new board, as well as manage its own capital. That capital will be primarily invested in acquisitions and research and development efforts, according to GE Healthcare's CEO for the U.S. and Canada.
With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be prepared to invest in quantum technologies to deliver better outcomes for their organizations and patients.
Covid changed things for medical affairs teams at pharmaceutical companies, causing was a fundamental shift in the way they worked and functioned. The role of the medical science liaison—a key member of the medical affairs team—has also evolved.
Clinton, Missouri-based Golden Valley Memorial Healthcare is the first to deploy Meditech's solution, Expanse Genomics. It allows providers to analyze and parse genetic results into actionable data that is displayed directly in patient charts, according to Meditech.
